Harel Insurance Investments & Financial Services Ltd. Has $575,000 Stock Position in Edwards Lifesciences Corporation $EW

Harel Insurance Investments & Financial Services Ltd. lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 33.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,353 shares of the medical research company’s stock after purchasing an additional 1,859 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Edwards Lifesciences were worth $575,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Jennison Associates LLC boosted its position in shares of Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares during the period. Nuveen LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $330,881,000. Invesco Ltd. boosted its position in shares of Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after purchasing an additional 198,882 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Mizuho increased their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research report on Friday, July 25th. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating in a research report on Monday. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Finally, Truist Financial raised their price objective on Edwards Lifesciences from $82.00 to $87.00 and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Edwards Lifesciences Stock Performance

Shares of EW opened at $82.48 on Monday. The company has a market capitalization of $48.42 billion, a PE ratio of 11.87, a PEG ratio of 3.97 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $87.09. The company’s 50 day moving average price is $77.58 and its 200 day moving average price is $76.97.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.